Model-based evaluation and optimization of cardiac monitoring protocols for adjuvant treatment of breast cancer with trastuzumab (scientific article published on 21 August 2012)

Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101--Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent tr

Q33973013

Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity

Q34189102

Adjuvant trastuzumab in HER2-positive breast cancer

Q35710898

Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy.

Q36836161

Left ventricular ejection fraction for sudden death risk stratification and guiding implantable cardioverter-defibrillators implantation

Q37761343

Lack of uniformity in cardiac assessment during trastuzumab therapy

Q39746124

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

Q42626922

ErbB2 is essential in the prevention of dilated cardiomyopathy.

Q43976647

Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis

Q44618270

Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin).

Q47323865

Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction

Q48469388

Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging.

Q51561367

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

Q53243856

Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.

Q54668841

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

Q61624905

Congestive Heart Failure in Older Women Treated With Adjuvant Anthracycline Chemotherapy for Breast Cancer

Q63365933

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment

Q81419131

Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and

Q84368801

P433

issue

P921

main subject

trastuzumab

Q412616

P304

page(s)

3499-3511

P577

publication date

2012-08-21

P1433

published in

Pharmaceutical Research

Q7180737

P1476

title

Model-based evaluation and optimization of cardiac monitoring protocols for adjuvant treatment of breast cancer with trastuzumab

P478

volume

Reverse relations

cites work (P2860)

Q35979543	Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin
Q41688591	Mechanistic Systems Modeling to Improve Understanding and Prediction of Cardiotoxicity Caused by Targeted Cancer Therapeutics.
Q36987975	Optimizing drug development of anti-cancer drugs in children using modelling and simulation
Q50079226	Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens
Q37161899	Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia

P356	DOI	10.1007/S11095-012-0845-Y
P698	PubMed publication ID	22907417